Navigation Links
Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
Date:4/29/2008

NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 /PRNewswire/ -- Foamix Ltd, a global leader in the development of dermatological foam medications and Galderma, a worldwide specialty pharmaceutical company focused on dermatology, today announced that they have signed an agreement to develop an innovative medicated foam jointly. This new treatment contains a novel drug for the therapy of certain skin diseases.

Under this agreement, Foamix will develop the foam formulation of the product and Galderma will subsequently conduct all other activities (clinical, non-clinical, etc). Foamix will receive staged payments on successful completion of the technical milestones of the project.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix is currently collaborating with 10 pharmaceutical companies on 11 projects in the development of proprietary dermatological and gynecologic foam drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation. Foamix holds 4 US patents and has 62 US patents pending, with further filings worldwide.

For additional information, please visit http://www.foamix.co.il.

About Galderma:

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company is present in 65 countries, with over 1,000 sales representatives and is committed to improving the health of skin with an extensive line of products to treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancers and medical solutions for skin senescence. With a new research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities devoted exclusively to dermatology. Leading dermatology brands include Differin(R), Rozex(R)/Metro(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R). Recently launched products include Pliaglis(TM), a topical anaesthetic for dermatologic procedures in the United-States, Epiduo(R), an innovative combination product for the acne treatment in Europe and Argentina, and Dysport(R), a botulinum toxin type A product for use in aesthetic medicine and dermatological indications in Brazil and Argentina.
The company's website is http://www.galderma.com.

For further information:

Foamix Galderma

Sigal Maymon Leila Zarif

Business Development Associate Head of Licensing

Tel: +972-8-9316233 Tel: +33(0)4-92-95-29-30

e-mail: info@foamix.co.il e-mail: leila.zarif@galderma.com


'/>"/>
SOURCE Foamix Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
4. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
5. Pregnant Women Need Omega-3 to Boost Infant Development
6. Aida Announces New Anti-Cancer Drug Under Development
7. ViroPharma Announces Discontinuation of HCV-796 Development
8. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
9. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 10, 2017   West Pharmaceutical Services, Inc. ... injectable drug administration, today shared the results of a ... improving the intradermal administration of polio vaccines. The study ... in May 2017 by Dr. Ondrej Mach , ... Health Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
Breaking Medicine News(10 mins):